Economic Burden of Fungal Diseases in the United States

Abstract

We conservatively estimated the US economic burden of fungal diseases as $11.5 billion in 2019: direct medical costs ($7.5 billion), productivity loss due to absenteeism ($870 million), and premature deaths ($3.2 billion). An alternative "value of statistical life"approach yielded >$48 billion. These are likely underestimates given underdiagnosis and underreporting.